Tarsa Therapeutics News

Tarsa Therapeutics Inc. has raised $7 million in new Series B funding. Return backers include Foresite Capital, MVM Life Science Partners, Quaker Partners and Novo A/S. The Philadelphia-based company is planning to file a new drug application with the FDA for an oral calcitonin tablet for the treatment of postmenopausal osteoporosis. www.tarsatherapeutics.com


©2017 PACT All Rights Reserved